In conclusion, this is the first preclinical study to demonstrate that combined ANT2 shRNA and hNIS radioiodine gene therapy 1) induces strong apoptosis and markedly up-regulates MHC class I and Fas gene expression levels in cancer cells in vitro and in vivo and 2) increases most killing activity of CTLs and generates remarkable tumor growth inhibition in an immunocompromised mouse colon cancer model. The gene discussed is FAS; the disease is neoplasm.